This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Butylphthalide
DrugBank Accession Number
DB12749
Background

Butylphthalide has been used in trials studying the prevention of Restenosis.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 190.2384
Monoisotopic: 190.099379692
Chemical Formula
C12H14O2
Synonyms
  • 3-n-butylphthalide
  • Butylphthalide

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding can be increased when Butylphthalide is combined with Abciximab.
AbrocitinibThe risk or severity of bleeding and thrombocytopenia can be increased when Butylphthalide is combined with Abrocitinib.
AceclofenacThe risk or severity of bleeding can be increased when Aceclofenac is combined with Butylphthalide.
AcemetacinThe risk or severity of bleeding can be increased when Acemetacin is combined with Butylphthalide.
AcenocoumarolThe risk or severity of bleeding can be increased when Butylphthalide is combined with Acenocoumarol.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Butylphthalide.
AlclofenacThe risk or severity of bleeding can be increased when Alclofenac is combined with Butylphthalide.
AldesleukinThe risk or severity of bleeding can be increased when Butylphthalide is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Butylphthalide is combined with Alemtuzumab.
AlteplaseThe risk or severity of bleeding can be increased when Butylphthalide is combined with Alteplase.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzofuranones. These are organic compounds containing a benzene ring fused to a furanone.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzofurans
Sub Class
Benzofuranones
Direct Parent
Benzofuranones
Alternative Parents
Phthalides / Benzenoids / Lactones / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aromatic heteropolycyclic compound / Benzenoid / Benzofuranone / Carboxylic acid derivative / Carboxylic acid ester / Hydrocarbon derivative / Isobenzofuranone / Isocoumaran / Lactone / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
822Q956KGM
CAS number
6066-49-5
InChI Key
HJXMNVQARNZTEE-UHFFFAOYSA-N
InChI
InChI=1S/C12H14O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h4-7,11H,2-3,8H2,1H3
IUPAC Name
3-butyl-1,3-dihydro-2-benzofuran-1-one
SMILES
CCCCC1OC(=O)C2=C1C=CC=C2

References

General References
Not Available
Human Metabolome Database
HMDB0032064
PubChem Compound
61361
PubChem Substance
347828938
ChemSpider
55293
RxNav
1484499
ChEMBL
CHEMBL248594
Wikipedia
Butylphthalide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentStroke, Acute, Stroke Ischemic1
4RecruitingPreventionCerebral Infarctions / Collateral Circulation / Large-artery Occlusion1
4RecruitingTreatmentCentral Nervous System Disorder / Cerebral Infarctions / Cerebrovascular Accident / Infarction, Brain / Ischemia, Brain / Nervous System Diseases / Vascular Diseases1
4Unknown StatusPreventionCerebrovascular Accident / Transient Ischemic Attack1
3CompletedPreventionRestenosis1
3CompletedTreatmentStroke, Acute, Stroke Ischemic1
3Not Yet RecruitingDiagnosticIschemic Cerebral Infarction / Ischemic Cerebrovascular Accident / Moyamoya Disease / Stroke, Ischemic / Transient Ischemic Attack1
3RecruitingTreatmentVascular Dementia (VaD)1
2, 3Unknown StatusTreatmentVascular Cognitive Impairment no Dementia1
Not AvailableActive Not RecruitingTreatmentNeuroprotection / Stroke, Ischemic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0654 mg/mLALOGPS
logP3ALOGPS
logP3.36ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.93ChemAxon
pKa (Strongest Basic)-6.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area26.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.78 m3·mol-1ChemAxon
Polarizability21.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 21, 2016 00:01 / Updated at February 21, 2021 18:53